436 Studies Now Enrolling
NU 10C03: Phase I/II Dose Escalation Trial to Assess Safety of Intrathecal Trastuzumab for the Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer
A study for patients with HER2 positive breast cancer using study drug Trastuzumab for treatment
| Sponsor: | Northwestern University |
| Enrolling: | Female Patients Only |
| IRB Number: | AAAO4157 |
| U.S. Govt. ID: | NCT01325207 |
| Contact: | Teri Kreisl: 212-342-0571 / tnk2109@cumc.columbia.edu |
Additional Study Information:
The purpose of this study is to gather information on the safety of TH-302 and its effect on patients with HER2+ breast cancer. This study will also look at how the drug is processed in the body. In addition, this study will collect data from blood, tumor, and imaging studies about this specific cancer such as the level of oxygen that is present. This may help us understand which patients may be more likely to be helped by TH-302.
This study is closed
